David Hubacher, PhD, MPH

Senior Epidemiologist

Areas of expertise

  • Epidemiology
  • Contraception
  • Clinical research
  • Intrauterine devices
  • Subdermal implants
  • Long-acting reversible contraception
  • Clinical trials
  • Health research
  • Family planning
  • Reproductive health

Projects & Resources

  • The goal of the Contraceptive Technology Innovation (CTI) Initiative is to develop new and strategically important contraceptives, through a strong focus on global partnerships, that ensures wide access to quality, affordable and acceptable products for those most in need.

  • FHI 360 developed and introduced innovative HIV prevention technologies — including microbicides and antiretrovirals — and worked with local partners to address the need for HIV prevention options, particularly for women.

Published Research

  • The levonorgestrel intrauterine system: Reasons to expand access to the public sector of Africa
    Hubacher D.
    Glob Health Sci Pract 2015 Dec; 3 (4): 532-7. [Journal Impact Factor: n/a]

    This paper provides a summary of the obstacles to interest in the levonorgestrel intrauterine system and six main reasons why donor agencies should purchase the levonorgestrel intrauterine system and why family planning programs should incorporate the method into their services. Women in resource-poor countries will benefit tremendously from the levonorgestrel intrauterine system, a successful and effective contraceptive.

  • Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya
    Todd CS, Deese J, Wang M, Hubacher D, Steiner MJ, Otunga S, Van Damme L, Fem-PrEP study group.
    Contraception 2014 Oct; epub ahead of print. [Journal Impact Factor: 2.932]

    As oral pre-exposure prophylaxis becomes more widely available, understanding the interaction of Truvada with other commonly used pharmaceuticals will become more important. In particular, reproductive-aged women at high risk of HIV are in need of highly effective methods both to protect themselves against HIV and to prevent pregnancy. This paper provides early data on the effect of Truvada on levonogestrel levels among women using Truvada for HIV prevention and Sino-implant (II) for contraception.

  • The levonorgestrel intrauterine system: Cohort study to assess satisfaction in a postpartum population in Kenya
    Hubacher D, Masaba R, Manduku CK, Chen M, Veena V
    Contraception 2015 Apr; 91 (4): 295-300. [Journal Impact Factor: 2.932]

    The levonorgestrel intrauterine system may soon be purchased by international donor agencies for use in public-sector programs in sub-Saharan Africa and resource-limited countries in other regions. The results of this study suggest that the product will be successful in future introduction activities. 

Explore More Related to David Hubacher, PhD, MPH